Emcure Pharmaceuticals IPO share allotment likely on Monday. Here’s how you can check the status.

Emcure Pharmaceuticals’ IPO has seen strong interest from investors, with the offer being nearly 68 times oversubscribed. The share allotment is expected to be finalised on Monday.

To check if you have been allotted shares, follow these steps on the BSE or the registrar’s website.

Checking on BSE

1. Visit the BSE Website: Go to this link.
2. Select the Issue Name: Choose “Emcure Pharmaceuticals” from the drop-down menu.
3. Enter Details: Input your application number or PAN number and click “Search”.

Checking via Link Intime India (Registrar)

1. Visit Link Intime India Website: Go to this link.
2. Select IPO: Choose “Emcure Pharmaceuticals IPO”.
3. Enter PAN Details: Input your PAN details and click “Search”.

Emcure Pharmaceuticals Grey Market Premium (GMP)

Emcure’s shares are trading at a ₹390 premium in the grey market. With the IPO price set at ₹1008, this suggests a potential gain of 38% on the listing day, which is scheduled for 10th July.

Key Investors and Fundraising

Before the IPO opened, Emcure raised ₹582 crore from anchor investors. Notable participants included HDFC Mutual Fund, ICICI Prudential Mutual Fund, SBI Mutual Fund, Abu Dhabi Investment Authority, Goldman Sachs Asset Management, Nomura, and HDFC Life.

Use of IPO Funds

The company plans to use the funds from the fresh issue to pay off debt and for general corporate purposes.

About Emcure Pharmaceuticals

Based in Pune, Emcure Pharmaceuticals develops, manufactures, and markets a wide range of pharmaceutical products worldwide. Their product portfolio includes orals, injectables, and biotherapeutics, targeting markets in over 70 countries, including India, Europe, and Canada.

Market Outlook

The global pharmaceutical market is projected to grow at a rate of 5.0% to 5.5% annually from 2023 to 2028, reaching approximately $1,900 billion (₹157 lakh crore) to $1,950 billion (₹161 trillion) by 2028.

For FY24, Emcure’s revenue grew 11% year-on-year to ₹6,658 crore, up from ₹5,985 crore the previous year. However, profit after tax fell 6% to ₹527 crore from ₹562 crore.

Lead Managers

Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the lead managers for the IPO.